ストックスクリーナーアプリを入手
96.93
0.31%
0.30
アフターアワーズ：
96.93
Merus N V (MRUS) 最新ニュース
Genmab completes $6.9 billion acquisition of Merus N.V., triggers leadership changes - Investing.com India
Merus Acquired by Genmab, Leadership Changes Announced - TipRanks
Genmab Completes Acquisition of Merus N.V. to Bolster Oncology Portfolio - TipRanks
Genmab Finalizes Tender Offer for Dutch Biotech Merus - marketscreener.com
Genmab Completes Acquisition of Merus – Bolsters Portfolio with New Cancer Treatment - marketscreener.com
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period - The AI Journal
Genmab: Completion of Tender Offer for Outstanding Common Shares of Merus N.V. - marketscreener.com
Genmab: Completion Of Tender Offer For Outstanding Common Shares Of Merus N.V. - TradingView
Genmab Announces Completion of Tender Offer for Outstanding - GlobeNewswire
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period - GlobeNewswire Inc.
How Genmab’s US$2.5 Billion Debt-Funded Merus Deal and Lymphoma Data Will Impact Genmab (CPSE:GMAB) Investors - simplywall.st
Insider Moves: Merus Executive Sells Significant Stock Holdings - TipRanks
(MRUS) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Genmab: How Its Combined Pipeline, Royalties & M&A Strategy Could Potentially Unlock A SOLID Upside! - Smartkarma
Merus Shareholders Approve Genmab Acquisition Proposal - TipRanks
Merus NV stock hits all-time high at 96.29 USD By Investing.com - Investing.com Canada
Merus NV stock hits all-time high at 96.29 USD - Investing.com
How Genmab’s US$2.5 Billion Merus Deal Financing Could Impact Genmab (CPSE:GMAB) Investors - Yahoo Finance
Saturn V Capital Management LP Has $11.80 Million Stock Position in Merus N.V. $MRUS - MarketBeat
Is Merus N.V. (2GH) stock included in top ETFs2025 Bull vs Bear & Daily Market Momentum Tracking - Newser
Can Merus N.V. stock outperform in 2025 bull marketQuarterly Growth Report & Capital Efficient Trade Techniques - Newser
Merus N.V. (MRUS): A Bull Case Theory - Finviz
Why institutional investors increase stakes in Merus N.V. (2GH) stockTrade Ideas & Technical Pattern Based Signals - Newser
What makes Merus N.V. (2GH) stock appealing to growth investorsWeekly Trend Recap & High Conviction Buy Zone Picks - Newser
Genmab closes $2.5 billion notes offering to fund Merus acquisition - Investing.com
Genmab closes $2.5 billion notes offering to fund Merus acquisition By Investing.com - Investing.com South Africa
Sio Capital Management LLC Purchases Shares of 62,719 Merus N.V. $MRUS - MarketBeat
Merus (MRUS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Quadrature Capital Ltd Buys New Position in Merus N.V. $MRUS - MarketBeat
Will Merus N.V. (2GH) stock return to pre crash levelsWeekly Profit Recap & Daily Oversold Stock Bounce Ideas - Newser
Can Merus N.V. (2GH) stock hold up in economic slowdownMarket Performance Recap & Risk Controlled Swing Trade Alerts - Newser
Merus N.V. $MRUS Shares Acquired by Ensign Peak Advisors Inc - MarketBeat
What analysts say about Merus NV stockEarnings Volatility Patterns & Free Transform Portfolio With Stocks - earlytimes.in
Merus (NASDAQ:MRUS) VP Harry Shuman Sells 8,300 Shares - MarketBeat
Responsive Playbooks and the MRUS Inflection - news.stocktradersdaily.com
Merus N.V.: VP controller Shuman sells $796k in shares By Investing.com - Investing.com Australia
ETFs investiert in Merus N.V.-Aktien - TradingView
Major Stock Sale Shakes Up Merus! - TipRanks
Merus N.V.: VP controller Shuman sells $796k in shares - Investing.com
Finance Watch: Lilly Toes The $1 Trillion Valuation Line - Citeline News & Insights
Halozyme Therapeutics (HALO): Evaluating Valuation Following New ENHANZE Partnership With Merus - simplywall.st
DNB Asset Management AS Sells 3,706 Shares of Merus N.V. $MRUS - MarketBeat
How cyclical is Merus N.V. (2GH) stock compared to rivalsTrade Ideas & Community Supported Trade Ideas - BỘ NỘI VỤ
Merus, Halozyme enter collaboration, license agreement for petosemtamab - MSN
Is Merus N.V. (2GH) stock positioned for digital growth eraJuly 2025 Trends & Accurate Intraday Trading Signals - moha.gov.vn
MRUS SC14D9C & SEC Filings - Yahoo Finance Australia
Does Merus Licensing Deal Signal a New Growth Phase for Halozyme Therapeutics (HALO)? - simplywall.st
Genmab Announces $2.5 Billion Note Offering for Merus Acquisition - MSN
Rare NRG1 Fusion Market Research Report 2025-2035 Featuring Merus, Hummingbird Bioscience, Elevation Oncology (Concentra Biosciences), and Shenzhen Salubris PharmaceuticalsResearchAndMarkets.com - Business Wire
1.08%
0.91%
大文字化:
|
ボリューム (24 時間):